Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RAPA 501

Next Previous
Search
Drug Profile

RAPA 501

Alternative Names: Allogeneic off-the-shelf RAPA-501 cells; Autologous Hybrid T-Cell Therapy - Rapa Therapeutics; Autologous hybrid TREG/Th2 cell therapy; RAPA-501; RAPA-501 Autologous T cells; RAPA-501 T cell therapy; RAPA-501-Allo cells

Latest Information Update: 19 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rapa Therapeutics
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Amyotrophic lateral sclerosis
  • Phase I/II SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 13 Dec 2023 Rapa Therapeutics initiates in an expanded access trial for Amyotrophic lateral sclerosis in USA (IV) (NCT06169176)
  • 30 Dec 2020 Phase-I/II clinical trials in SARS-COV-2 acute respiratory disease (Late-stage disease) in USA (IV) (NCT04482699)
  • 15 Dec 2020 Phase-II/III clinical trials in Amyotrophic lateral sclerosis in USA (IV) (NCT04220190)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top